In this edition:
Anti-PD-L1 therapy +/- chemotherapy for NSCLC
Adagrasib in advanced/metastatic NSCLC harboring a KRAS mutation
Amivantamab for NSCLC with MET exon 14 skipping mutation
Neoadjuvant nivolumab + chemotherapy for resectable stage IIIA NSCLC
Comprehensive molecular genotyping and OS in advanced non-squamous NSCLS
Intraoperative quality metrics and survival after lung cancer resection
QoL with once- vs twice-daily thoracic radiotherapy in LS-SCLC
Pathological regression with neoadjuvant nivolumab in resectable NSCLC
Tiragolumab in ES-SCLC
Ramucirumab + pembrolizumab for ICI-exposed NSC
Please login below to download this issue (PDF)